| Literature DB >> 31417234 |
Suthasinee Sinawat1, Thawinee Trisakul1, Stephanie Choi2, Michael Morley2, Supat Sinawat3, Yosanan Yospaiboon1.
Abstract
PURPOSE: To elucidate the clinical manifestations, management, and visual outcomes of patients with ocular angiostrongyliasis.Entities:
Keywords: Angiostrongylus canthnensis; intraocular parasite; ocular angiostrongyliasis; raw food
Year: 2019 PMID: 31417234 PMCID: PMC6592067 DOI: 10.2147/OPTH.S204380
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Patient demographic data, ocular findings, management, and visual outcome
| Sex | Age (y) | Meningitis | Duration (weeks) | Ocular exam (initial) | Investigation | Treatment | Final VA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eye | Location | VA | RAPD | Ocular findings | Eosino-philia | Stool exam (eggs) | Laser | Antihelminthic | Steroid | PR | |||||
| M | 27 | Preceded | 3 | Left | Intravitreal | 1/60 | + | Chorioretinitis, subretinal track | – | NA | + | Albendazole ×7 | Topical prednisolone | + | 1/60 |
| M | 21 | Coexisting | 1 | Left | Intravitreal | 2/60 | + | RPE alteration | + | NA | + | — | Oral prednisolone | – | 2/60 |
| M | 47 | — | 3 | Left | Intracameral | CF | + | RPE alteration, disk swelling, intraretinal hge | NA | Sarcocystis Opisthorchis | + | Albendazole ×14 | IV, oral, topical prednisolone | + | 1/60 |
| F | 44 | — | 0.5 | Right | Subretinal | LP | + | Subconjunctival hge subretinal track, serous RD, macular opacification, peripapillary hge, vitreous hge | NA | Not found | + | Albendazole ×14, ivermectin once | Oral, topical prednisolone | – | no LP |
| F | 36 | Preceded | 1 | Left | Intravitreal | CF | + | RPE alteration, disk swelling | + | NA | + | — | Oral prednisolone | + | CF |
| F | 41 | — | 4 | Left | Subtenon | 6/6 | – | Conjunctival injection | NA | – | Albendazole ×7 | Topical prednisolone, subconjunctival dexa | + | 6/6 | |
| M | 50 | — | 2 | Left | Subretinal | CF | + | RPE alteration, subretinal track | + | Not found | + | Albendazole ×7 | Topical prednisolone | + | CF |
| M | 76 | — | 2 | Right | Intracameral | 6/60 | – | Corneal scar, | NA | Opisthorchis | – | Praziquantel ×7 | Topical prednisolone | + | 6/36 |
| F | 63 | — | 8 | Left | Intracameral | LP | – | Corneal scar, hyphema, vitreous hge, preretinal hge | – | Not found | – | Albendazole ×7 | Topical prednisolone, Subconjunctival dexa | + | HM |
| F | 51 | — | 2 | Left | Intravitreal* | HM | – | Focal iris atrophy, choroiditis | + | + | Albendazole ×7 | Topical prednisolone | – | HM | |
| F | 22 | — | 8 | Right | Intravitreal | 1/60 | + | RPE alteration, disk swelling | – | NA | – | — | Oral prednisolone | + | 1/60 |
| F | 28 | — | 0.5 | Right | Subretinal | 6/24 | – | Subretinal track | – | NA | + | — | Oral prednisolone | – | 6/24 |
| M | 36 | — | 1 | Right | Subretinal | CF | + | Macular edema | NA | Echinostoma | + | Albendazole ×7 | Topical prednisolone | + | 2/60 |
| M | 39 | — | 1.5 | Right | Intravitreal | 6/6 | – | — | NA | NA | + | — | — | – | 6/6 |
| F | 33 | — | 1 | Left | Subretinal | 1/60 | + | RPE alteration | – | NA | + | — | Oral prednisolone | – | 5/60 |
| M | 27 | — | 4 | Right | Subretinal | CF | + | Subretinal track | NA | NA | + | Albendazole ×7 | - | – | CF |
| M | 46 | — | 3 | Right | Intracameral | CF | + | RPE alteration, vitritis | – | NA | + | — | Oral, topical prednisolone | + | CF |
| M | 46 | — | 1 | Right | Intravitreal | CF | + | RPE alteration, vitritis | – | Not found | + | Albendazole ×7 | Topical prednisolone | + | 6/60 |
Note: *The parasite migrated from anterior chamber to vitreous cavity.
Abbreviations: VA, visual acuity; CF, counting finger; hge, hemorrhage; HM, hand motion; LP, light perception; PR, parasitic removal; RPE, retinal pigment epithelium; dexa, dexamethasone; RAPD, relative afferent pupillary defect; NA, not available.
Figure 1Angiostrongylus cantonensis larvae in subtenon space (A), aqeous humour (B), vitreous cavity (C), and subretinal space (D).
Figure 2Large subretinal angiostrongyliasis with severe disk hemorrhage and extensive retinal whitening.